Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ALX Oncology Holdings Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALXO
Nasdaq
8731
https://alxoncology.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ALX Oncology Holdings Inc
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
- Apr 24th, 2024 2:00 pm
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
- Apr 15th, 2024 11:31 am
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
- Apr 11th, 2024 1:30 pm
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
- Apr 9th, 2024 9:30 pm
ALX Oncology Holdings Inc (ALXO) Insider Sells Shares
- Apr 6th, 2024 5:33 am
ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer
- Mar 8th, 2024 8:48 pm
ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending
- Mar 8th, 2024 3:41 am
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Mar 7th, 2024 9:03 pm
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
- Mar 5th, 2024 9:30 pm
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 1:00 pm
7 Small-Cap Stocks That Wall Street Loves for Good Reason
- Dec 22nd, 2023 9:21 pm
ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments
- Nov 13th, 2023 9:47 pm
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 13th, 2023 9:05 pm
ALX Oncology Announces November Investor Conference Participation
- Nov 1st, 2023 8:05 pm
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Oct 10th, 2023 8:05 pm
While institutions invested in ALX Oncology Holdings Inc. (NASDAQ:ALXO) benefited from last week's 74% gain, private equity firms stood to gain the most
- Oct 9th, 2023 3:26 pm
The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna
- Oct 6th, 2023 8:59 am
Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More
- Oct 5th, 2023 2:58 pm
ALX Oncology Announces Pricing of Public Offering
- Oct 5th, 2023 12:00 pm
ALX Oncology Announces Proposed Public Offering
- Oct 4th, 2023 8:10 pm
Scroll